Amanda Rajapaksa
Stanford University
6 Papers
46 Citations
Amanda Rajapaksa is an academic researcher from Stanford University. The author has contributed to research in topics: Cancer & Lymphoma. The author has an hindex of 4, co-authored 6 publications.
Chat about Author
Papers
Three BTK-Specific Inhibitors, in Contrast to Ibrutinib, Do Not Antagonize Rituximab-Dependent NK-Cell Mediated Cytotoxicity
Narendiran Rajasekaran,Mohith Sadaram,Jonathan Hebb,Idit Sagiv-Barfi,Sid Ambulkar,Amanda Rajapaksa,Serena Chang,Cariad Chester,Erin Waller,Lai Wang,Brian J. Lannutti,Dave Johnson,Ronald Levy,Holbrook E Kohrt +13 more
TL;DR: The BTK inhibitor, ibrutinib is FDA-approved in MCL and CLL, with activity in the majority of CD20+ B-cell malignancies, and is clinically effective as monotherapy and in combination with rituximab despite inhibition of ADCC in vitro and in vivo murignancies.
25
Biomarker characterization using mass cytometry in a phase 1 trial of urelumab (BMS-663513) in subjects with advanced solid tumors and relapsed/refractory B-cell non-Hodgkin lymphoma.
Cariad Chester,Serena Chang,John F. Kurland,Idit Sagiv-Barfi,Debra K. Czerwinski,Amanda Rajapaksa,Erin Waller,Mohith Sadaram,Lori Richards,Lewis J. Cohen,Christoph Matthias Ahlers,Maria Jure-Kunkel,Holden T. Maecker,Ronald Levy,Holbrook E Kohrt +14 more
TL;DR: The novel technology of mass cytometry time of flight (CyTOF) was employed to investigate the patient's global immune status prior to and during a phase 1 study of Urelumab, a fully human anti-CD137 antibody, administered once per 3-week cycle in patients with solid tumors and B-cell non-Hodgkin’s lymphoma.
11
Abstract 2941: Local tumor irradiation combined with α-PDL-1 immune checkpoint inhibition results in local and systemic anti-tumor responses: Successful translation of a mouse model to a human case series
Idit Sagiv-Barfi,Amanda Rajapaksa,Debra K. Czerwinski,Serena Chang,Jonathan Hebb,Cariad Chester,Erin Waller,Gregg Fine,Daniel S. Chen,Marcin Kowanetz,Bryan Irving,Ronald Levy,Holbrook E Kohrt +12 more
TL;DR: The magnitude of the immune response and abscopal response rate in mice and humans provides proof-of-concept that anti-PD-L1 may be an equally if not more potent combination immunotherapy with radiation compared to the authors' experience with CpG and/or anti-CTLA4.
7
Targeting CD137 to enhance the antitumor efficacy of cetuximab by stimulation of innate and adaptive immunity.
Holbrook E Kohrt,Roch Houot,Kipp Weiskopf,Matthew J. Goldstein,Peder Lund,Ruth R Lira,Emily Troutner,Lori Richards,Amanda Rajapaksa,Anton Ostashko,Wen-Kai Weng,Lieping Chen,Debra K. Czerwinski,A. Dimitrios Colevas,John B. Sunwoo,Ronald Levy +15 more
TL;DR: The hypothesis that the combination of cetuximab with anti-CD137 mAb will enhance innate and adaptive immunity, thereby improving cetUXimab’s anti-tumor efficacy in preclinical models and a prospective trial, is investigated.
4
Sequential tumor and dual immune targeted immunotherapy: anti-lymphoma activity of Rituximab with 4-1bb stimulation and PD-1 blockade.
Antonia Ms Mueller,Jonathan Hebb,Idit Sagiv-Barfi,Aurélien Marabelle,Roch Houot,Amanda Rajapaksa,Debra K. Czerwinski,Serena Chang,Cariad Chester,Mohith Sadaram,Erin Waller,Ronald Levy,Holbrook E Kohrt +12 more
TL;DR: It is concluded that sequential tumor-targeting followed by dual immune- targeting is highly-efficacious with predictable toxicity and should be considered for clinical translation to augment three therapies with only marginal activity as monotherapy in advanced, relapsed/refractory lymphoma.
2